News

The AB-rated product is a therapeutically equivalent alternative to the antiepileptic Felbatol (a registered trademark of Meda Pharmaceuticals). The Amneal generic is available in two sizes, 8 fl

IPX066 is a patented extended release capsule formulation of carbidopa-levodopa (CD-LD), intended to maintain consistent plasma concentration of levodopa. The NDA includes data from three controlled Phase III

AZD1419 is a second-generation TLR-9 agonist for asthma. The cost of development will be fully funded by AstraZeneca, and Dynavax will receive payment of $2.6m to begin the

The ingredients by SourceOne comprise specialized formulations of EPA/DHA Omega-3 oils, Citrus Polymethoxylated Flavonoids, TocoSource Palm Tocotrienols, and VESIsorb (which is designed to enhance bioavailability of a variety

The randomized trial, called BATON-CRC, will enroll approximately 252 patients with no prior VEGF-targeted therapy at approximately 80 centers in the US, Canada, Australia and Europe, the company

GlaxoSmithKline will retain the existing rights for these products in countries outside the US. Terms of the agreement have not been disclosed. GSK will manufacture and supply Fortaz

Initiation of the trial entitles Dynavax to receive a $6m milestone payment from GlaxoSmithKline (GSK) under their worldwide strategic alliance. GSK has an exclusive option to obtain a

GSK’s portfolio of 17 OTC brands comprises pain relievers BC, Goody’s and Ecotrin; gastrointestinal brands Beano, Gaviscon, Phazyme, Tagamet, and Fiber Choice; and Sominex sleep aids. According to

The collaboration is focused on developing potential drug candidates to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis. In March 2011,